SBHMY Dividend: Sino Biopharmaceutical Ltd Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

SBHMY Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	30,566	28,866	26,199	26,026	26,861	23,647
Revenue Growth (YoY)	14%	10%	1%	-3%	14%	-2%
Cost of Revenue	5,572	5,336	4,989	4,487	5,332	5,182
Gross Profit	24,994	23,529	21,209	21,538	21,529	18,464
Selling, General & Admin	12,854	12,159	11,066	11,708	12,763	11,628
Research & Development	5,698	5,089	4,402	4,164	3,677	2,626
Operating Expenses	19,705	17,437	15,263	15,845	16,749	14,093
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	7,630	5,277	5,409	5,214	18,572	5,013
Income Tax Expense	860	492	797	696	1,957	672
Net Income	3,871	3,499	2,331	2,543	14,608	2,771
Net Income Growth	-5%	50%	-8%	-83%	426.99%	0%
Shares Outstanding (Diluted)	18,025.87	18,295.06	18,529.06	19,017.2	19,282.95	18,800.28
Shares Change (YoY)	-2%	-1%	-3%	-1%	3%	0%
EPS (Diluted)	0.21	0.19	0.12	0.13	0.75	0.14
EPS Growth	-2%	57.99%	-8%	-83%	409%	0%
Free Cash Flow	--	5,655	4,997	5,021	3,652	3,830
Free Cash Flow Per Share	--	0.3	0.26	0.26	0.18	0.2
Gross Margin	81.77%	81.51%	80.95%	82.75%	80.14%	78.08%
Operating Margin	17.3%	21.1%	22.69%	21.87%	17.79%	18.48%
Profit Margin	12.66%	12.12%	8.89%	9.77%	54.38%	11.71%
Free Cash Flow Margin	--	19.59%	19.07%	19.29%	13.59%	16.19%
EBITDA	--	7,384	6,992	6,699	5,750	5,981
EBITDA Margin	--	25.58%	26.68%	25.73%	21.4%	25.29%
D&A For EBITDA	--	1,292	1,047	1,007	971	1,610
EBIT	5,288	6,092	5,945	5,692	4,779	4,371
EBIT Margin	17.3%	21.1%	22.69%	21.87%	17.79%	18.48%
Effective Tax Rate	11.27%	9.32%	14.73%	13.34%	10.53%	13.4%